56 research outputs found

    Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

    Get PDF
    Despite generally high cure rates in patients with metastatic germ cell cancer, patients with progressive disease on first-line cisplatin-based chemotherapy or with relapsed disease following high-dose salvage therapy exhibit a very poor prognosis. Irinotecan has shown antitumour activity in human testicular tumour xenografts in nude mice. We have performed a phase II study examining the single agent activity of irinotecan in patients with metastatic relapsed or cisplatin-refractory germ cell cancer. Refractory disease was defined as progression or relapse within 4 weeks after cisplatin-based chemotherapy or relapse after salvage high-dose chemotherapy with autologous stem cell support. Irinotecan was administered at a dose of 300 (−350) mg m−2 every 3 weeks. Response was evaluated every 4 weeks. Fifteen patients have been enrolled. Median age was 35 (19–53) years. Primary tumour localisation was gonadal/mediastinal in 12/3 patients. Patients had been pretreated with a median of six (4–12) cisplatin-containing cycles and 13 out of 15 patients had previously failed high-dose chemotherapy with blood stem cell support. Median number of irinotecan applications was two (1–3). Fourteen patients are assessable for response and all for toxicity. In one patient, no adequate response evaluation was performed. Toxicity was generally acceptable and consisted mainly of haematological side effects with common toxicity criteria 3° anaemia (two patients), common toxicity criteria 3° leukocytopenia (one patient) and common toxicity criteria 3° thrombocytopenia (three patients). Common toxicity criteria 3/4° non-haematological toxicity occurred in five patients (33%): 1×diarrhoea, 2×alopecia, 1×fever and in one patient worsening of pre-existing peripheral polyneuropathy from 1° to 4°. No response was observed to irinotecan therapy. Currently, 13 patients have died of the disease and two patients are alive with the disease. The patients included in our study exhibit similar prognostic characteristics as patients treated in previous trials evaluating new drugs in this setting. Irinotecan at a dose of 300–350 mg m−2 every 3 weeks appears to have no antitumour activity in patients with cisplatin-refractory germ cell cancer and, thus, further investigation in this disease is not justified

    Endothelzelldichte 5 Jahre nach Implantation einer phaken kammerwinkelgestützten Vorderkammer-Intraokularlinse (PIOL)

    No full text

    Die kammerwinkelgestützte phake Acrysof Cachet-IOL - 1-Jahres Ergebnisse

    No full text

    Implementation of an urban operations simulation model

    No full text
    The implementation of a basic simulation framework for urban operation scenarios, using the discrete event simulation tool IMPRINT, is presented. Preliminary stages of problem definition, system analysis and modeling are described. The model consists of task nodes representing essential processes in urban operations (e.g., room clearing) that are controlled and coordinated by a platoon leader. In the basic framework, the architecture and size of the urban task environment and the platoon size are used as independent variables. For exemplary purposes, the model has been parameterized in terms of task duration, based on small samples from field observation. In prospective studies, the framework will be extended by independent variables such as forces' gear, experience and team structure and by dependent variables based on a database for human performance and workload parameters

    Eine neuartige phake vorderkammerwinkelgestützte Intraokularlinse - Evolution, Implantation und Ergebnisse

    No full text
    • …
    corecore